Curadel Pharma

Curadel Pharma is an audacious innovator aiming to prevent tumor resistance via disruptive zwitterionic radiopharma technology. Its novel, pan-tumor platform prevents tumor regrowth and resistance while eliminating collateral damage to healthy tissues. Curadel’s lead candidate, CPI-003, represents a potential best-in-class zwitterionic targeted alpha therapy (TAT) initially focused on the treatment of challenging rare cancers. The company is also developing image-guided surgical drugs. Its late-stage drug for ureter imaging is currently under evaluation in a pivotal trial. Curadel was founded by zwitterionicity pioneer John V. Frangioni, M.D., Ph.D., Professor of Medicine (Emeritus) and Professor of Radiology (Emeritus) at Harvard Medical School.